J
The FDA issued its first approval of a CRISPR gene-editing therapy.
The US Food and Drug Administration announced the approval of two gene-based therapies for sickle cell disease, one of which uses the genome editing technology CRISPR. It’s a big milestone, but access to the therapies for now will still be very limited and expensive, the New York Times explains.
Follow topics and authors from this story to see more like this in your personalized homepage feed and to receive email updates.
Loading comments
Getting the conversation ready...
Most Popular
Most Popular
- Good riddance, Cybertruck!
- Anker’s new window-mounted camera monitors the outside of your home from within it
- I’ve reviewed almost every Android foldable this year — here’s how the iPhone Duo compares
- Why a new report on Anthropic automating AI development is alarming researchers
- KPop Demon Hunters on 4K Blu-ray costs less than a month of Netflix Premium
